Anavex Life Sciences has released promising results from its latest clinical study on ANAVEX2-73, also
known as blarcamesine, aimed at treating Parkinson’s Disease Dementia (PDD).
The announcement follows the completion of a 48-week open-label extension of
their Phase 2 trial, which demonstrated significant improvements in PDD-related symptoms.
Despite initial delays due to the COVID-19 pandemic, participants who resumed treatment with
blarcamesine exhibited noteworthy advancements in key clinical metrics.
According to Anavex reports, these included enhancements in
Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)
scores and Clinical Global Impression-Improvement (CGI-I) ratings. The trial’s
encouraging results highlight ANAVEX2-73’s potential to address the urgent
unmet needs of the PDD patient population.
The trial enrolled 132 participants, who were randomly assigned to receive either 30 mg, 50 mg of
blarcamesine, or a placebo. After the double-blind period, many patients opted
to continue under a compassionate use program, thereby extending the study’s reach
and impact. Notably, the treatment did not impair sleep, a common concern in
Parkinson’s disease management, and even showed positive effects on REM sleep behavior.
Christopher U. Missling, PhD, President and CEO of Anavex Life Sciences, expressed optimism
over the findings, as they suggest that blarcamesine could play a significant
role in mitigating the progression of PDD symptoms. This data paves the way for
Anavex’s future studies, which are planned to further explore the efficacy and
safety of blarcamesine.
The outcomes from this study add to the growing body of evidence supporting Anavex’s innovative
approach to neurodegenerative diseases, reinforcing its emerging role in the
field of neurological therapeutics. As research continues, the medical
community is keenly observing whether these promising results will translate
into broader clinical applications. See related link for
more information.
Follow their page on https://www.instagram.com/anavexlifesci/